Ovarian Cancer: Bevacizumab as Adjuvant Treatment—Not Yet

被引：0
|
作者：
Amit Agarwal
机构：
[1] B L Kapoor Memorial Hospital,
来源：
Indian Journal of Gynecologic Oncology | 2017年 / 15卷 / Suppl 1期
关键词：
Bevacizumab (BEV); High-risk Ovarian Cancer; Post-progression Treatment; Significant Residual Disease; Improved Progression Free Survival;
D O I：
10.1007/s40944-017-0165-6
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：9 / 10
页数：1
相关论文
共 50 条
  • [31] ECONOMIC EVALUATION OF BEVACIZUMAB FOR THE TREATMENT OF ADVANCED OVARIAN CANCER IN MEXICO
    Lechuga, D.
    Alva, M.
    Carlos, F.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A221 - A221
  • [32] Bevacizumab in the First-line Treatment of advanced Ovarian Cancer
    Mallmann, Michael R.
    Alakus, Hakan
    Mallmann, Peter
    Bruns, Christiane
    [J]. ONKOLOGE, 2019, 25 (11): : 1020 - 1021
  • [33] Our experience with bevacizumab in the primary treatment of epithelial ovarian cancer
    Erik, Skof
    Dusan, Mangaroski
    [J]. ONKOLOGIJA, 2020, 24 (01) : 20 - 24
  • [34] Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer
    Richardson, D. L.
    Backes, F. J.
    Seamon, L. G.
    O'Malley, D. M.
    Cohn, D. E.
    Fowler, J. M.
    Copeland, L. J.
    [J]. GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S13 - S13
  • [35] Bevacizumab for the treatment of epithelial ovarian cancer: Will this be its finest hour?
    Kaye, Stanley B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5150 - 5152
  • [36] The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer
    Zhang, Wenwen
    Shen, Zhaojun
    Luo, Hui
    Hu, Xiaoli
    Zheng, Lihong
    Zhu, Xueqiong
    [J]. CURRENT DRUG TARGETS, 2017, 18 (10) : 1125 - 1131
  • [37] Bevacizumab for the treatment of recurrent ovarian cancer: a retrospective cohort study
    Akers, S. N.
    Riebandt, G.
    Miller, A.
    Groman, A.
    Odunsi, K.
    Lele, S.
    [J]. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2013, 34 (02) : 113 - 119
  • [38] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer EDITORIAL COMMENT
    Burger, Robert A.
    Brady, Mark F.
    Bookman, Michael A.
    Fleming, Gini F.
    Monk, Bradley J.
    Huang, Helen
    Mannel, Robert S.
    Homesley, Howard D.
    Fowler, Jeffrey
    Greer, Benjamin E.
    Boente, Matthew
    Birrer, Michael J.
    Liang, Sharon X.
    [J]. OBSTETRICAL & GYNECOLOGICAL SURVEY, 2012, 67 (05) : 289 - 290
  • [39] Profile of bevacizumab in the treatment of platinumresistant ovarian cancer: current perspectives
    McClung, E. Clair
    Wenham, Robert M.
    [J]. INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2016, 8 : 59 - 75
  • [40] Predictive biomarkers for bevacizumab in the first line treatment of ovarian cancer
    Jayson, Gordon
    [J]. ANGIOGENESIS, 2014, 17 (03) : 727 - 727
12345